107 related articles for article (PubMed ID: 1965755)
1. Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer. Analysis of 45 cases.
Hori M; Furusato M; Nikaidoh T; Aizawa S
Acta Pathol Jpn; 1990 Dec; 40(12):902-7. PubMed ID: 1965755
[TBL] [Abstract][Full Text] [Related]
2. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
Domagala W; Lasota J; Bartkowiak J; Weber K; Osborn M
Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of the topographical relationship between the estrogen- and progesterone receptor in five human breast cancers. A simultaneous demonstration of both nuclear receptors in the same section by using a computer-assisted image processing.
Bonkhoff H; Wernert N
Virchows Arch A Pathol Anat Histopathol; 1989; 414(4):339-44. PubMed ID: 2540591
[TBL] [Abstract][Full Text] [Related]
4. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
6. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.
Marchetti E; Querzoli P; Marzola A; Bagni A; Ferretti S; Fabris G; Nenci I
Mod Pathol; 1990 Jan; 3(1):31-5. PubMed ID: 2308919
[TBL] [Abstract][Full Text] [Related]
7. A comparison between Ki-67 antibody reactivity and other pathological variables in breast carcinoma.
Bilous AM; McKay M; Milliken J
Pathology; 1991 Oct; 23(4):282-5. PubMed ID: 1664511
[TBL] [Abstract][Full Text] [Related]
8. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
9. [An immunohistochemical investigation of estrogen receptor in human breast cancer].
Hori M; Furusato M; Aizawa S; Tanaka H; Uchida K
Gan No Rinsho; 1990 Feb; 36(2):143-7. PubMed ID: 1689780
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
11. Potential value of hormone receptor assay in carcinoma in situ of breast.
Barnes R; Masood S
Am J Clin Pathol; 1990 Nov; 94(5):533-7. PubMed ID: 2173395
[TBL] [Abstract][Full Text] [Related]
12. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
13. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.
Shaaban AM; O'Neill PA; Davies MP; Sibson R; West CR; Smith PH; Foster CS
Am J Surg Pathol; 2003 Dec; 27(12):1502-12. PubMed ID: 14657709
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical assessment of ER-P31, a mouse anti-oestrogen receptor protein monoclonal antibody in human breast cancers: comparison with ER-ICA (Abbott) and radioligand assays.
Wong SY; Purdie A; Sewell HF; Wilkinson L; Angus B; Westley B; Horne CH
Tumour Biol; 1991; 12(1):16-23. PubMed ID: 1705046
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor expression and proliferation in breast cancer cells, studied with flow cytometry.
Scheres HM; Schutte B; De Goij AF; Bosman FT
Acta Histochem Suppl; 1990; 40():71-6. PubMed ID: 2091049
[No Abstract] [Full Text] [Related]
16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
17. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Takagi K; Miki Y; Nakamura Y; Hirakawa H; Kakugawa Y; Amano G; Watanabe M; Ishida T; Sasano H; Suzuki T
Histol Histopathol; 2015 Oct; 30(10):1223-32. PubMed ID: 25873048
[TBL] [Abstract][Full Text] [Related]
18. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
19. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
20. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
